Research programme: anticancer therapeutics - S*BIO

Drug Profile

Research programme: anticancer therapeutics - S*BIO

Alternative Names: EX2; EX44; EX45; EX58; SB1304; SB1354; SB2312; SB2602

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator S*BIO
  • Developer National University of Singapore; S*BIO
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Enzyme inhibitors; Fms-like tyrosine kinase 3 inhibitors; Histone deacetylase inhibitors; Janus kinase-2 inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Singapore (PO)
  • 29 Aug 2013 This programme is still active
  • 31 Mar 2010 Pacritinib, pracinostat, CT 1578, TG 02 and VS 5584 have been outlicensed prior to March 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top